Literature DB >> 12218383

Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.

Mario Clerici1, Claudia Barassi, Claudia Devito, Claudia Pastori, Stefania Piconi, Daria Trabattoni, Renato Longhi, Jorma Hinkula, Kristina Broliden, Lucia Lopalco.   

Abstract

BACKGROUND: HIV-specific IgA is present in HIV-exposed uninfected individuals (EU) and neutralizes primary strains of HIV-1 in vitro.
OBJECTIVES: To analyse the antigenic correlates of HIV-1 neutralization using HIV epitopes and IgA from EU and HIV-seropositive individuals.
METHODS: Sera from six heterosexual couples discordant for HIV serostatus, six age-matched HIV-infected subjects and six healthy controls (HC; as negative controls) were analysed. IgA binding on HIV Env recombinant proteins was assayed. Serum IgA was affinity purified on specific Env peptides and tested in HIV neutralization using resting and activated peripheral blood mononuclear cells as target. Monoclonal antibody 2F5 was used as neutralizing positive control. BALB/c mice were immunized with specific gp41 peptide and anti-sera were tested in syncytia formation and in HIV viral replication.
RESULTS: IgA of EU exclusively bound an epitope within gp41; this epitope was restricted to residues 582-588 (QARILAV) and corresponded to the leucine zip motif in the alpha-helical region. IgA of HIV-positive patients recognized epitopes expressed both in gp120 and gp41; these epitopes were in the N-terminal portion of the extramembrane region. Additionally, IgA of EU and antisera of QARILAV-immunized Balb/C mice blocked syncytia formation and viral replication. The dose-dependent neutralization behaviour of specific QARILAV-purified IgA was very similar to that obtained with monoclonal antibody 2F5.
CONCLUSION: These results have important implications for the development of vaccines and therapeutical strategies against HIV infection. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218383     DOI: 10.1097/00002030-200209060-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

Authors:  Claudia Pastori; Barbara Weiser; Claudia Barassi; Caterina Uberti-Foppa; Silvia Ghezzi; Renato Longhi; Giliola Calori; Harold Burger; Kimdar Kemal; Guido Poli; Adriano Lazzarin; Lucia Lopalco
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

3.  HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies.

Authors:  Genevieve G Fouda; Nicole L Yates; Justin Pollara; Xiaoying Shen; Glenn R Overman; Tatenda Mahlokozera; Andrew B Wilks; Helen H Kang; Jesus F Salazar-Gonzalez; Maria G Salazar; Linda Kalilani; Steve R Meshnick; Beatrice H Hahn; George M Shaw; Rachel V Lovingood; Thomas N Denny; Barton Haynes; Norman L Letvin; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Sallie R Permar
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

4.  Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses.

Authors:  Gleb Kichaev; Janess M Mendoza; Dinah Amante; Trevor R F Smith; Jay R McCoy; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Vaccin Immunother       Date:  2013-06-11       Impact factor: 3.452

Review 5.  Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN).

Authors:  C Tomescu; S Abdulhaqq; L J Montaner
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

6.  HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Authors:  Jennifer M Lund; Kristina Broliden; Maria N Pyra; Katherine K Thomas; Deborah Donnell; Elizabeth Irungu; Timothy R Muwonge; Nelly Mugo; Madhuri Manohar; Marianne Jansson; Romel Mackelprang; Mark A Marzinke; Jared M Baeten; Jairam R Lingappa
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

7.  Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.

Authors:  Adriano Boasso; Monica Vaccari; Dietmar Fuchs; Andrew W Hardy; Wen-Po Tsai; Elzbieta Tryniszewska; Gene M Shearer; Genoveffa Franchini
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

8.  Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.

Authors:  Rosemary Stevens; Kristina E Howard; Sushila Nordone; MaryJo Burkhard; Gregg A Dean
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease.

Authors:  Wei Jiang
Journal:  Am J Immunol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.